| Literature DB >> 31663791 |
Maria Arkoumani1,2, Nektaria Papadopoulou-Marketou1,2, Nicolas C Nicolaides2, Christina Kanaka-Gantenbein2, Nikolaos Tentolouris3, Ioannis Papassotiriou1.
Abstract
Growth differentiation factor-15 (GDF-15), also known as macrophage inhibitory cytokine-1 (MIC-1) or non-steroidal anti-inflammatory drug-activated gene (NAG-1) has been identified as a biomarker of response to treatment and prognosis in cardiovascular diseases. GDF-15 is a member of the transforming growth factor-β superfamily and is involved in several pathological conditions such as inflammation, cancer, cardiovascular, pulmonary and renal diseases. Cardiac myocytes produce and secrete GDF-15 in response to oxidative stress, stimulation with angiotensin II or proinflammatory cytokines, ischemia, and mechanical stretch. Other cellular sources of GDF-15 production are macrophages, vascular smooth muscle cells, endothelial cells, and adipocytes, which secrete GDF-15 in response to oxidative or metabolic stress or stimulation of proinflammatory cytokines. GDF-15 is induced in hypertrophic and dilated cardiomyopathy after volume overload, ischemia, and heart failure. GDF-15 can be used as a marker of prognosis in patients with cardiovascular disorders, in combination with conventional prognostic factors, such as N-terminal pro B-type natriuretic peptide (NT-proBNP) and high-sensitivity troponin T (hs-TnT).Entities:
Keywords: GDF-15; biomarkers; heart; stroke
Mesh：
Substances：
Year: 2019 PMID： 31663791 DOI： 10.1080/10408363.2019.1678565
Source DB: PubMed Journal: Crit Rev Clin Lab Sci ISSN： 1040-8363 Impact factor: 6.250